Back to search

Article

Safety and Exploratory Efficacy of Reduced β-Nicotinamide Mononucleotide Calcium Salt (NMNH-Ca) in Healthy Middle-Aged and Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

2026-08-12

Abstract excerpt

Reduced nicotinamide mononucleotide (NMNH) is a reduced NAD⁺ precursor with reported NAD⁺-augmenting activity in preclinical models; however, controlled human data remain limited. This was a randomized, double-blind, placebo-controlled, parallel-group phase I trial evaluating oral NMNH-Ca in healthy adults aged 40-65 years. Eighty participants received placebo or NMNH-Ca 125, 250, or 500 mg once daily for 90 days....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f9a47efa-4745-516e-9abc-553d36f574d7
DOI
10.64898/2026.08.11.26360226
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and Exploratory Efficacy of Reduced β-Nicotinamide Mononucleotide Calcium Salt (NMNH-Ca) in Healthy Middle-Aged and Older Adults: A Randomized, Double-Blind, Placebo-Controlled TrialDOI 10.64898/2026.08.11.26360226
Select a neighboring publication to make it the new centre.